Tango Therapeutics, Inc. filings document a clinical-stage precision oncology business and its Nasdaq-listed common stock. Current reports disclose operating and financial results, business highlights for vopimetostat and related development programs, material agreements, capital-raising arrangements such as at-the-market common stock sales, and updates to governance and executive leadership.
Proxy and compensation disclosures cover board matters, executive pay, pay-versus-performance data, equity awards, and shareholder voting matters. The company’s filings also address officer appointments and departures, separation and employment agreements, compensatory arrangements, capital structure, risk factors, and other material events affecting its biotechnology operations.
TNGX reports a proposed sale of 93,000 shares of Common Stock related to the exercise of stock options on 03/25/2026 for cash. The filing also lists prior Rule 10b5-1 sales by Adam Crystal, including 20,251, 54,345, and 18,452 shares on 03/05/2026, 02/25/2026, and 02/03/2026, respectively.
Tango Therapeutics, Inc. President of R&D Crystal Adam reported an open-market sale of 20,251 shares of common stock at $15.00 per share. After this transaction, she directly owned 112,622 shares of Tango Therapeutics common stock.
The sale was executed on March 5, 2026 and is described as an open-market or private transaction. According to a footnote, these trades were carried out under a pre-established Rule 10b5-1 trading plan adopted on October 27, 2025, which automates transactions under preset instructions.
Adam Crystal submitted a Form 144 reporting proposed dispositions of Common stock tied to option exercises and restricted stock units, and disclosing recent 10b5-1 sales. The filing lists an exercise of stock options for 15,000 shares on 03/05/2026 (cash), and restricted stock units totaling 5,251 with an award date of 02/03/2025.
The filing also reports completed 10b5-1 sales by Adam Crystal: 54,345 shares sold on 02/25/2026 for $694,208.46, and 18,452 shares sold on 02/03/2026 for $226,300.30.
Tango Therapeutics, Inc. reported fourth quarter and full-year 2025 results and provided pipeline and corporate updates. Cash, cash equivalents and marketable securities totaled $343.1 million as of December 31, 2025, which the company expects will fund operations into 2028.
Collaboration revenue was $62.4 million for 2025, up from $30.0 million in 2024, mainly reflecting recognition of remaining Gilead deferred revenue. Research and development expenses declined to $132.2 million from $143.9 million, while net loss narrowed to $101.6 million, or $0.87 per share, from $130.3 million, or $1.19 per share. The company highlighted progress for lead PRMT5 inhibitor vopimetostat, plans for a pivotal 2L pancreatic cancer study in 2026, new combination collaborations, and leadership changes including a new CEO and Chief Regulatory Officer.
Tango Therapeutics, Inc. files its 2025 annual report outlining an advanced pipeline of precision oncology programs built around synthetic lethality and biomarker-driven patient selection.
The company highlights vopimetostat (TNG462), a PRMT5 inhibitor for MTAP‑deleted cancers, with Phase 1/2 monotherapy data showing a 27% objective response rate and 6.4‑month median progression‑free survival across 94 evaluable patients, including 7.2‑month median progression‑free survival and 25% response rate in second‑line MTAP‑deleted pancreatic cancer. A histology‑selective cohort reported a 49% response rate and 9.1‑month median progression‑free survival. Combination trials with RAS(ON) inhibitors daraxonrasib and zoldonrasib are under way, along with a new collaboration with Erasca’s pan‑RAS agent ERAS‑0015.
TNG456, a brain‑penetrant PRMT5 inhibitor, is in a Phase 1/2 trial for MTAP‑deleted solid tumors with a focus on glioblastoma, supported by pharmacokinetics suggesting adequate central nervous system exposure; earlier candidate TNG908 was discontinued after subtherapeutic brain exposure. TNG961, an HBS1L degrader for FOCAD‑deleted/MTAP‑deleted tumors, remains in IND‑enabling development. CoREST inhibitor TNG260, combined with pembrolizumab, delivered a 29‑week median progression‑free survival in a five‑patient subgroup of checkpoint‑inhibitor‑resistant STK11‑mutant/KRAS wild‑type non‑small cell lung cancer, more than double the ~10‑week standard of care, and is continuing in that genetically defined cohort.
Tango Therapeutics, Inc. reported that Crystal Adam, its President, R&D, sold 54,345 shares of common stock on February 25, 2026. The open-market sale was executed at a weighted average price of $12.7741 per share under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025. Following this transaction, Adam directly owns 132,873 Tango Therapeutics common shares.
Adam Crystal filed a Form 144 reporting sales of company common stock. The filing lists 54,345 Restricted Stock Units identified for sale and reports 18,452 shares sold on 02/03/2026 for $226,300.30.
The filing names Morgan Stanley Smith Barney LLC as the broker and shows transaction and security details tied to restricted stock units dated 02/05/2024.
Tango Therapeutics, Inc. (TNGX) received an amended Schedule 13G/A showing that EcoR1 Capital, LLC, EcoR1 Capital Fund Qualified, L.P., and Oleg Nodelman now report zero beneficial ownership of the company’s common stock. As of December 31, 2025, each reporting person lists 0 shares beneficially owned and a 0% stake, with no sole or shared voting or dispositive power. The filing confirms they own 5 percent or less of the class. The parties also state they are filing jointly but expressly disclaim being part of a group and disclaim beneficial ownership beyond any pecuniary interest.
Tango Therapeutics, Inc. received an amended Schedule 13G from TCG Crossover Fund II, TCG Crossover GP II, and Chen Yu reporting beneficial ownership of 13,521,839 shares of common stock, representing 9.99% of the class.
The position consists of 12,762,094 common shares and 759,745 shares underlying pre-funded warrants that are exercisable within 60 days of the statement. Additional pre-funded warrants for up to 1,066,666 shares are excluded because a 9.99% Beneficial Ownership Limitation prevents exercise above that threshold. Ownership is calculated using 134,593,998 shares outstanding as of October 28, 2025, plus the exercisable warrant shares. The filers state the securities are not held for the purpose of changing or influencing control of Tango.
Woodline Partners LP filed an amended beneficial ownership report showing a significant passive stake in Tango Therapeutics, Inc.. Woodline reports beneficial ownership of 10,072,225 shares of Tango common stock, representing 7.5% of the class.
The percentage is calculated using 134,677,094 shares of common stock outstanding as of November 1, 2025, as disclosed in a company registration statement. Woodline, a Delaware investment adviser, reports sole voting and dispositive power over these shares, which are directly held by Woodline Master Fund LP.
The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Tango Therapeutics. Woodline Master Fund has the right to receive dividends and sale proceeds from more than 5% of the common stock.